Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Genkyotex

ENXTPA:GKTX
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GKTX
ENXTPA
€23M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Genkyotex has significant price volatility in the past 3 months.
GKTX Share Price and Events
7 Day Returns
3.9%
ENXTPA:GKTX
4.3%
FR Biotechs
1.8%
FR Market
1 Year Returns
-76.9%
ENXTPA:GKTX
-31.6%
FR Biotechs
-17.5%
FR Market
GKTX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genkyotex (GKTX) 3.9% -9.4% -3.9% -76.9% -90.7% -
FR Biotechs 4.3% -10.9% -26.4% -31.6% -63.4% -71.1%
FR Market 1.8% -12.1% -24.9% -17.5% -7.6% -7.2%
1 Year Return vs Industry and Market
  • GKTX underperformed the Biotechs industry which returned -31.6% over the past year.
  • GKTX underperformed the Market in France which returned -17.5% over the past year.
Price Volatility
GKTX
Industry
5yr Volatility vs Market

GKTX Value

 Is Genkyotex undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Genkyotex. This is due to cash flow or dividend data being unavailable. The share price is €1.975.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genkyotex's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genkyotex's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:GKTX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.88
ENXTPA:GKTX Share Price ** ENXTPA (2020-04-08) in EUR €1.98
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
France Market PE Ratio Median Figure of 411 Publicly-Listed Companies 13.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genkyotex.

ENXTPA:GKTX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:GKTX Share Price ÷ EPS (both in EUR)

= 1.98 ÷ -0.88

-2.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genkyotex is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Genkyotex is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does Genkyotex's expected growth come at a high price?
Raw Data
ENXTPA:GKTX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-106.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
France Market PEG Ratio Median Figure of 253 Publicly-Listed Companies 1.01x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genkyotex, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genkyotex's assets?
Raw Data
ENXTPA:GKTX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €1.17
ENXTPA:GKTX Share Price * ENXTPA (2020-04-08) in EUR €1.98
France Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 2.22x
France Market PB Ratio Median Figure of 591 Publicly-Listed Companies 1.16x
ENXTPA:GKTX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:GKTX Share Price ÷ Book Value per Share (both in EUR)

= 1.98 ÷ 1.17

1.68x

* Primary Listing of Genkyotex.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genkyotex is good value based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess Genkyotex's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Genkyotex has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GKTX Future Performance

 How is Genkyotex expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-106.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genkyotex expected to grow at an attractive rate?
  • Unable to compare Genkyotex's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Genkyotex's earnings growth to the France market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Genkyotex's revenue growth to the France market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ENXTPA:GKTX Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:GKTX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -106.3%
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 21.6%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 34.9%
France Market Earnings Growth Rate Market Cap Weighted Average 12.2%
France Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:GKTX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:GKTX Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 0 -72 -72 1
2020-12-31 0 -12 -12 1
2020-04-08
ENXTPA:GKTX Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 -7
2019-09-30 -9
2019-06-30 -9 -11
2019-03-31 -9 -11
2018-12-31 -9 -11
2018-09-30 -9 -11
2018-06-30 -8 -10
2018-03-31 -9 -18
2017-12-31 -9 -26
2017-09-30 -9 -26
2017-06-30 -9 -27
2017-03-31 -7 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genkyotex is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Genkyotex is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:GKTX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Genkyotex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:GKTX Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -6.19 -6.19 -6.19 1.00
2020-12-31 -1.03 -1.03 -1.03 1.00
2020-04-08
ENXTPA:GKTX Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.88
2019-09-30 -1.14
2019-06-30 -1.43
2019-03-31 -1.44
2018-12-31 -1.46
2018-09-30 -1.38
2018-06-30 -1.30
2018-03-31 -2.49
2017-12-31 -3.90
2017-09-30 -5.47
2017-06-30 -9.00
2017-03-31 -10.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genkyotex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Genkyotex's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genkyotex has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GKTX Past Performance

  How has Genkyotex performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genkyotex's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genkyotex does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Genkyotex's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genkyotex's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Genkyotex's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genkyotex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:GKTX Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -7.20 2.16 5.41
2019-09-30 -9.23 2.57 6.42
2019-06-30 -11.27 2.97 7.44
2019-03-31 -11.34 2.96 7.85
2018-12-31 -11.42 2.95 8.27
2018-09-30 -10.80 3.07 7.88
2018-06-30 -10.18 3.20 7.50
2018-03-31 -17.98 4.28 8.08
2017-12-31 -25.77 5.36 8.66
2017-09-30 -26.15 5.14 7.87
2017-06-30 -26.52 4.92 7.07
2017-03-31 -16.61 3.41 5.54
2016-12-31 -6.70 1.89 4.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genkyotex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genkyotex has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genkyotex improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genkyotex's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genkyotex has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GKTX Health

 How is Genkyotex's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genkyotex's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genkyotex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genkyotex's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genkyotex's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genkyotex Company Filings, last reported 3 months ago.

ENXTPA:GKTX Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 9.84 0.87 2.42
2019-09-30 9.84 0.87 2.42
2019-06-30 11.09 2.22 4.46
2019-03-31 11.09 2.22 4.46
2018-12-31 14.44 3.64 10.31
2018-09-30 14.44 3.64 10.31
2018-06-30 19.07 0.29 9.34
2018-03-31 19.07 0.29 9.34
2017-12-31 23.54 0.40 11.35
2017-09-30 23.54 0.40 11.35
2017-06-30 29.32 0.45 14.85
2017-03-31 29.32 0.45 14.85
2016-12-31 12.22 0.00 13.94
  • Genkyotex's level of debt (6.8%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Genkyotex's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Genkyotex's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Genkyotex's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genkyotex has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GKTX Dividends

 What is Genkyotex's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genkyotex dividends.
If you bought €2,000 of Genkyotex shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genkyotex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genkyotex's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:GKTX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
France Market Average Dividend Yield Market Cap Weighted Average of 297 Stocks 3.8%
France Minimum Threshold Dividend Yield 10th Percentile 1.2%
France Bottom 25% Dividend Yield 25th Percentile 2%
France Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:GKTX Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genkyotex has not reported any payouts.
  • Unable to verify if Genkyotex's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genkyotex's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genkyotex has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genkyotex's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genkyotex afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genkyotex has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GKTX Management

 What is the CEO of Genkyotex's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Elias Papatheodorou
COMPENSATION €649,243
AGE 50
TENURE AS CEO 4.6 years
CEO Bio

Mr. Ilias Papatheodorou, also known as Elias, has been the Chief Executive Officer at Genkyotex SA since September 30, 2015 and as its Director since February 28, 2017. Mr. Papatheodorou served as Chief Business Officer of Genkyotex S.A. from March 2015 to September 30, 2015. Mr. Papatheodorou served as the Chief Business Officer of Covagen AG since April 15, 2013 and was instrumental in the closing of a CHF46 million series B round and in the subsequent sale of Covagen to Jannsen Pharmaceuticals, a J&J Company. Mr. Papatheodorou served as a Senior Vice President of Business Development and Vice President of Business Development and operations at MediGene AG, where he negotiated the original deal between Medigene and Syncore. He served as Chief Executive Officer at Novosom AG. He joined novosom AG in September 2004. He has 13 years experience in the life science sector with a track record of fundraising and collaborative agreements. Mr. Papatheodorou served as Vice President of marketing, sales and business development at ATI Medical Imaging. During his tenure, signed multi-million agreements with companies such as Amgen, Janssen, J&J, Medicus, Medtronic, Novartis, CBS, Discovery Network as well as collaborations agreements with the NIH, Siemens Medical and Zeiss. Mr. Papatheodorou was also involved in discussions with a number of leading pharmaceutical and biotechnology companies. Prior to ATI, he worked in various positions for The Coca-Cola Company and Philip Morris Inc. In his tenure the Smarticles technology entered clinical trials in the U.S.A., Smarticles technology raised funds and closed licensing deals with Isis Pharmaceuticals (NASDAQ: ISIS) and ProNAi Therapeutics. He serves as the Head of the Board of Priaxon AG and as Board member of Protatonce. He engineered the sale of Novosom's assets to Marina Biotech (MRNA). Mr. Papatheodorou received his undergraduate education at Ithaca College, NY and his graduate education at Cornell University, NY.

CEO Compensation
  • Elias's compensation has increased whilst company is loss making.
  • Elias's remuneration is higher than average for companies of similar size in France.
Management Team

Elias Papatheodorou

TITLE
CEO & Director
COMPENSATION
€649K
AGE
50
TENURE
4.6 yrs

Karl-Heinz Krause

TITLE
Founder & Member of Scientific Advisory Board

Alexandre Grassin

TITLE
Vice President of Finance & Administration

Philippe Wiesel

TITLE
Chief Medical Officer & Executive VP
TENURE
4.6 yrs

Cedric Merlot

TITLE
Consultant of Knowledge Management & Computational Chemistry
Board of Directors Tenure

Average tenure and age of the Genkyotex board of directors in years:

3.2
Average Tenure
57.5
Average Age
  • The tenure for the Genkyotex board of directors is about average.
Board of Directors

Claudio Nessi

TITLE
Chairman of the Board
AGE
51
TENURE
3.2 yrs

Elias Papatheodorou

TITLE
CEO & Director
COMPENSATION
€649K
AGE
50
TENURE
3.2 yrs

Karl-Heinz Krause

TITLE
Founder & Member of Scientific Advisory Board

Robert Clark

TITLE
Chairman of Scientific Advisory Board

Gilles Nobecourt

TITLE
Director
AGE
62
TENURE
11.8 yrs

Catherine Moukheibir

TITLE
Independent Director
COMPENSATION
€30K
AGE
60
TENURE
3.2 yrs

Chihiro Yabe-Nishimura

TITLE
Member of Scientific Advisory Board

Jesus Martin-Garcia

TITLE
Director
AGE
57
TENURE
3.2 yrs

Stephane Verdood

TITLE
Observer
AGE
58
TENURE
3.2 yrs

Dave Lambeth

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Genkyotex's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genkyotex has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GKTX News

Simply Wall St News

Is Genkyotex (EPA:GKTX) Using Debt In A Risky Way?

Importantly, Genkyotex SA (EPA:GKTX) does carry debt. … ENXTPA:GKTX Historical Debt, August 14th 2019 A Look At Genkyotex's Liabilities We can see from the most recent balance sheet that Genkyotex had liabilities of €6.76m falling due within a year, and liabilities of €996.0k due beyond that. … Overall, its balance sheet doesn't seem overly risky, at the moment, but we're always cautious until we see the positive free cash flow.

Simply Wall St -

Imagine Owning Genkyotex (EPA:GKTX) And Trying To Stomach The 76% Share Price Drop

See our latest analysis for Genkyotex With just €375,000 worth of revenue in twelve months, we don't think the market considers Genkyotex to have proven its business plan. … A Different Perspective While Genkyotex shareholders are down 76% for the year, the market itself is up 8.1%. … But note: Genkyotex may not be the best stock to buy.

Simply Wall St -

Those Who Purchased Genkyotex (EPA:GKTX) Shares A Year Ago Have A 44% Loss To Show For It

Investors in Genkyotex SA (EPA:GKTX) have tasted that bitter downside in the last year, as the share price dropped 44%. … We wouldn't rush to judgement on Genkyotex because we don't have a long term history to look at. … With just €375,000 worth of revenue in twelve months, we don't think the market considers Genkyotex to have proven its business plan.

Simply Wall St -

What Type Of Shareholder Owns Genkyotex SA's (EPA:GKTX)?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Genkyotex is a smaller company with a market capitalization of €80m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

What You Must Know About Genkyotex SA's (EPA:GKTX) Major Investors

In this article, I'm going to take a look at Genkyotex SA’s (EPA:GKTX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … A company's ownership structure is often linked to its share performance in both the long- and short-term. … Therefore, it is beneficial for us to examine GKTX's ownership structure in more detail.

Simply Wall St -

GKTX Company Info

Description

Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company’s lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in angiogenesis, pain processing, and inflammation. Genkyotex SA has a licence agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Labège, France.

Details
Name: Genkyotex SA
GKTX
Exchange: ENXTPA
Founded: 2006
€22,791,985
11,540,246
Website: http://www.genkyotex.com
Address: Genkyotex SA
516 Rue Pierre et Marie Curie,
Labège,
Midi-Pyrénées, 31670,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA GKTX Common Shares Euronext Paris FR EUR 01. Mar 2017
DB G061 Common Shares Deutsche Boerse AG DE EUR 01. Mar 2017
BATS-CHIXE GKTXP Common Shares BATS 'Chi-X Europe' GB EUR 01. Mar 2017
Number of employees
Current staff
Staff numbers
13
Genkyotex employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:50
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/02/27
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.